95%Confidence
0Views
FDASource
2026-03-03Date
Summary
Fourth Asteria Health recall extends to estradiol pellets, confirming cross-product contamination risks. This could disrupt hormone replacement therapy markets and increase regulatory pressure on compounding pharmacies.
Actionable: Recall all Asteria Health products from inventory and notify healthcare providers of contamination risks.
AI Confidence: 95%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productESTRADIOL, 25 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-3025-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now